If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Usewww.notificaram.es. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Do not store above 25°C.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date appearing on the bottle and on the box afterCAD. The expiration date is the last day of the month indicated.
Do not use this medication if the capsules show any type of damage.
Medications should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
The active ingredient is lisdexamfetamine dimesilate.
Each hard capsule of 70 mg contains 70 mg of lisdexamfetamine dimesilate, corresponding to 20.8 mg of dexamfetamine.
The other components are :
•Hard capsule content:microcrystalline cellulose, croscarmellose sodium, magnesium stearate.
•Hard capsule coating:gelatin, black ink (shellac and iron oxide black (E172)).
•Colorants of the hard capsule coating:titanium dioxide (E171), brilliant blue FCF (E133) and erythrosine (E127).
Appearance of the product and contents of the package
Hard capsules.
The 70 mg capsules have a blue opaque body and a pink opaque cap, with the impression “S489” and “70 mg” in black ink.
Package size: 28 or 30 capsules. Some package sizes may only be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2, D02 HW68, Ireland
Email: [email protected]
Responsible manufacturer:
Shire Pharmaceuticals Ireland Limited
Block 2 & 3 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
Ireland
or
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50 – 58 Baggot Street Lower
Dublin 2, D02 HW68
Ireland
or
Takeda GmbH,
Plant Oranienburg, Lehnitzstrasse 70-98,
16515 Oranienburg
Germany
Further information about this medicinal product can be obtained by contacting the local representative of the marketing authorization holder:
Takeda Farmacéutica España S.A.
Calle Albacete, 5, planta 9ª,
Edificio Los Cubos
28027 Madrid
Spain
Phone: +34 91 790 42 22
This medicinal product is authorized in the Member States of the European Economic Area and inUnited Kingdom (Northern Ireland)with the following names:
GermanyElvanse
AustriaElvanse
BelgiumElvanse
DenmarkElvanse
SpainElvanse
FinlandElvanse
NetherlandsElvanse
IrelandTyvense
LuxembourgElvanse
NorwayElvanse
PortugalElvanse
SwedenElvanse
United Kingdom (Northern Ireland) Elvanse
Last review date of this leaflet: 12/2023.
For detailed and updated information about this medicinal product, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.